A Phase 2 interventional study of Placebo and PF-00547659 SC Injection in Ulcerative Colitis, sponsored by Shire. Completed at 190 sites in 21 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-06-11.
Sponsored by Shire (part of Takeda) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 68 studies in Colitis, Ulcerative by Takeda — 6 open to participants now, 10 under way, 5 of them phase 3. Colitis, Ulcerative · Takeda.
Among the 68 studies in Colitis, Ulcerative by Takeda, this one is the 13th largest by enrollment of the 43 interventional ones that give a count, is one of 2 that started in 2012, is one of 10 in phase 2, and was the 14th registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →6 of the 68 studies in Colitis, Ulcerative by Takeda are open now, in 12 countries. Recruiting first, the newest first:
Takeda · Sites in United States, Belgium, Bulgaria and 11 more countries
Ages 2–17
Takeda · Sites in United States, China, Czechia and 5 more countries
Ages 18–75
Takeda · Sites in United States
Ages 18–80
Takeda · Sites in United States, Belgium, Bulgaria and 13 more countries
Ages 2–17
Takeda · Sites in Korea, Republic of
Ages 18+
By country, each count listing its studies:
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
68 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 357 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 240 across the 43 interventional studies, 372 across the 24 observational. Of the 54 that completed or were terminated, 35 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
4 of the studies in Colitis, Ulcerative by Takeda that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03221036Phase 3TakedaEfficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis | 2027-09-24 |
| NCT06581328TakedaA Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting | 2027-05-01 |
| NCT06095128TakedaA Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC) | 2027-07-09 |
| NCT05428345TakedaA Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea | 2027-11-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 68 studies in Colitis, Ulcerative by Takeda, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To determine the dose or doses of PF-00547659 that will be the most effective to improve or halt the disease symptoms in patients with moderate to severe ulcerative colitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Placebo
Drug: PF-00547659 SC Injection
Drug: PF-00547659 SC Injection
Drug: PF-00547659 SC Injection
Drug: PF-00547659 SC Injection
Placebo delivered subcutaneous injection, 3 doses separated by 4 weeks
Drug Dose Level 1 delivered subcutaneous injection, 3 doses separated by 4 weeks
Drug Dose Level 2 delivered subcutaneous injection, 3 doses separated by 4 weeks
Drug Dose Level 3 delivered subcutaneous injection, 3 doses separated by 4 weeks
Drug Dose Level 4 delivered subcutaneous injection, 3 doses separated by 4 weeks
Percentage of Participants in Clinical Remission at Week 12
Clinical remission was defined as a Total Mayo Score of less than or equal (\<=) 2 points with no individual subscore exceeding 1 point and rectal bleed subscore of 0 or 1. The Mayo Score is a tool designed to measure disease activity for ulcerative colitis (UC). Scoring ranges from 0 to 12 points and consists of 4 subscores, each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopic readings from the local and the central reader were considered for analysis. The central reading was used as the primary analysis and the local readings were used for the sensitivity analyses.
Time frame: Week 12
Percentage of Participants With Clinical Response at Week 12
Clinical response was defined as a decrease from baseline of at least 3 points in Total Mayo Score with at least a 30 percent (%) change, accompanied by at least 1 point decrease or absolute score of 0 or 1 in rectal bleeding subscore. The Mayo Score is a tool designed to measure disease activity for UC. Scoring ranges from 0 to 12 points and consists of 4 subscores, each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopic readings from the local and the central reader were considered for analysis. The central reading was used as the primary analysis and the local readings were used for the sensitivity analyses.
Time frame: Week 12
Percentage of Participants With Mucosal Healing at Week 12
Mucosal healing was defined as absolute Mayo subscore for endoscopy of 0 or 1. The Mayo Score is a tool designed to measure disease activity for UC. Scoring ranges from 0 to 12 points and consists of 4 subscores, each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopic readings from the local and the central reader were considered for analysis. The central reading was used as the primary analysis and the local readings were used for the sensitivity analyses.
Time frame: Week 12
Percentage of Participants With Absolute Partial Mayo Score of Less Than or Equal to (<=) 2 With no Individual Subscore More Than (>) 1 at Weeks 4, 8, and 12
An absolute Partial Mayo Score of \<=2 corresponds to remission. However, this endpoint was incorrectly stated in the protocol and instead of "absolute Partial Mayo Score \<=2", it was stated as "change from baseline in Partial Mayo Score \<=2".
Time frame: Weeks 4, 8, and 12
Change From Baseline in Total Mayo Score at Week 12
The Mayo Score is a tool designed to measure disease activity for UC. Scoring ranges from 0 to 12 points and consists of 4 subscores, each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopic readings from the local and the central reader were considered for analysis. The central reading was used as the primary analysis and the local readings were used for the sensitivity analyses.
Time frame: Baseline, Week 12
Percentage of Participants With Change From Baseline in Individual Mayo Subscores - Stool Frequency, Rectal Bleeding, and Physician's Global Assessment (PGA) - at Weeks 4, 8, and 12
The Mayo Score is a tool designed to measure disease activity for UC. Scoring ranges from 0 to 12 points and consists of 4 subscores (stool frequency, rectal bleeding, PGA, findings on flexible sigmoidoscopy), each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopic readings from the local and the central reader were considered for analysis. The central reading was used as the primary analysis and the local readings were used for the sensitivity analyses. Changes from baseline in the subscore of less than (\<) 0, 0, and \>0 corresponded to improvement (imp), no change (NC), and worsening (wors) in that specific subscore.
Time frame: Baseline; Weeks (W) 4, 8, and 12
Percentage of Participants With Change From Baseline in Individual Mayo Subscore - Findings on Flexible Sigmoidoscopy - at Week 12
The Mayo Score is a tool designed to measure disease activity for UC. Scoring ranges from 0 to 12 points and consists of 4 subscores (stool frequency, rectal bleeding, PGA, findings on flexible sigmoidoscopy), each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopic readings from the local and the central reader were considered for analysis. The central reading was used as the primary analysis and the local readings were used for the sensitivity analyses. Changes from baseline in the subscore of \<0, 0, and \>0 corresponded to improvement (imp), no change (NC), and worsening (wors) in that specific subscore.
Time frame: Baseline, Week 12
Percent Change From Baseline in Fecal Calprotectin at Weeks 4, 8, and 12
Fecal calprotectin was one of the pharmacodynamic (PD) biomarkers of the study.
Time frame: Baseline, Weeks 4, 8, and 12
Percent Change From Baseline in High Sensitivity C-reactive Protein (hsCRP) at Weeks 4, 8, and 12
hsCRP was one of the PD biomarkers of the study.
Time frame: Baseline; Weeks 4, 8, and 12
Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 12
IBDQ: Psychometrically validated patient reported outcome (PRO) instrument for measuring disease-specific quality of life (QOL) in participants with inflammatory bowel disease. IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). Total score is the sum of each item score, ranged from 32 to 224 with higher score indicating better QOL. Positive change in total score indicated improvement in QOL.
Time frame: Baseline, Week 12
Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Domain Scores at Week 12
IBDQ: Psychometrically validated PRO instrument for measuring disease-specific QOL in participants with inflammatory bowel disease. IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). Total score is the sum of each item score, ranged from 32 to 224 with higher score indicating better QOL. Positive change in total score indicated improvement in QOL. There are 4 individual domains under the IBDQ: bowel function (fx)/symptoms (score range of 10-70), systemic symptoms (score range of 5-35), emotional status/fx (score range of 12-84), and social fx (score range of 5-35). As with total score, higher scores indicate better QOL in that domain.
Time frame: Baseline (BL), Week 12
Percentage of Participants With an Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score of More Than or Equal to (>=) 170 at Week 12
IBDQ: Psychometrically validated PRO instrument for measuring disease-specific QOL in participants with inflammatory bowel disease. IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). Total score is sum of each item score, ranged from 32 to 224 with higher score indicating better QOL. Positive change in total score indicated improvement in QOL. A score of \>=170 corresponds to clinical remission.
Time frame: Week 12
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Withdrawals Due to TEAEs During the Treatment Period (Weeks 0-12)
An adverse event (AE) was any untoward medical occurrence attributed to study drug in a participant who received study drug. TEAEs are defined as newly occurring AEs or those worsening after first dose. AEs comprised both SAEs and non-SAEs. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Time frame: Screening through to end of treatment period, up to 12 weeks
Maximum Serum PF-00547659 Concentration Achieved
Time frame: Weeks 0 (baseline), 2, 4,8, 12, 16, 20, 24, 28, 32, and 36; Early Withdrawal
| Milestone | Placebo | PF-00547659 7.5 mg | PF-00547659 22.5 mg | PF-00547659 75 mg | PF-00547659 225 mg |
|---|---|---|---|---|---|
| Started | 73 | 71 | 70 | 73 | 70 |
| Treated | 73 | 71 | 70 | 73 | 70 |
| Completed | 69 | 65 | 68 | 70 | 64 |
| Not completed | 4 | 6 | 2 | 3 | 6 |
| Withdrew: Withdrawal by subject | 4 | 1 | 1 | 2 | 4 |
| Withdrew: Participant underwent fecal transplant | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Non-compliance | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 4 | 0 | 1 | 1 |
| Withdrew: Withdrawn at discretion of investigator | 0 | 0 | 0 | 0 | 1 |
Clinical remission was defined as a Total Mayo Score of less than or equal (\<=) 2 points with no individual subscore exceeding 1 point and rectal bleed subscore of 0 or 1. The Mayo Score is a tool designed to measure disease activity for ulcerative colitis (UC). Scoring ranges from 0 to 12 points and consists of 4 subscores, each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopic readings from the local and the central reader were considered for analysis. The central reading was used as the primary analysis and the local readings were used for the sensitivity analyses.
| percentage of participants | Placebo | PF-00547659 7.5 mg | PF-00547659 22.5 mg | PF-00547659 75 mg | PF-00547659 225 mg |
|---|---|---|---|---|---|
| Centrally read | 2.7 (0.7 to 7.6) | 11.3 (5.7 to 18.8) | 16.7 (9.9 to 25.4) | 15.5 (9.5 to 23.6) | 5.7 (2.5 to 12.5) |
| Locally read | 5.5 (2.4 to 12.0) | 14.1 (7.8 to 22.0) | 23.6 (15.6 to 33.1) | 18.3 (11.9 to 27.1) | 12.9 (7.3 to 21.1) |
Clinical response was defined as a decrease from baseline of at least 3 points in Total Mayo Score with at least a 30 percent (%) change, accompanied by at least 1 point decrease or absolute score of 0 or 1 in rectal bleeding subscore. The Mayo Score is a tool designed to measure disease activity for UC. Scoring ranges from 0 to 12 points and consists of 4 subscores, each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopic readings from the local and the central reader were considered for analysis. The central reading was used as the primary analysis and the local readings were used for the sensitivity analyses.
| percentage of participants | Placebo | PF-00547659 7.5 mg | PF-00547659 22.5 mg | PF-00547659 75 mg | PF-00547659 225 mg |
|---|---|---|---|---|---|
| Centrally read (n=73,71,72,71,70) | 28.8 (20.2 to 37.8) | 38.0 (28.4 to 47.6) | 54.2 (44.2 to 64.2) | 45.1 (35.0 to 55.3) | 50.0 (39.6 to 60.4) |
| Locally read (n=73,70,72,70,70) | 32.9 (24.2 to 42.3) | 38.6 (28.8 to 48.1) | 54.2 (44.2 to 64.2) | 48.6 (38.2 to 59.0) | 51.4 (41.0 to 61.8) |
Mucosal healing was defined as absolute Mayo subscore for endoscopy of 0 or 1. The Mayo Score is a tool designed to measure disease activity for UC. Scoring ranges from 0 to 12 points and consists of 4 subscores, each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopic readings from the local and the central reader were considered for analysis. The central reading was used as the primary analysis and the local readings were used for the sensitivity analyses.
| percentage of participants | Placebo | PF-00547659 7.5 mg | PF-00547659 22.5 mg | PF-00547659 75 mg | PF-00547659 225 mg |
|---|---|---|---|---|---|
| Centrally read | 8.2 (3.6 to 15.4) | 15.5 (9.5 to 23.6) | 27.8 (19.5 to 37.1) | 25.4 (17.1 to 35.0) | 14.3 (8.0 to 22.3) |
| Locally read | 21.9 (14.9 to 31.4) | 22.5 (15.4 to 31.6) | 37.5 (28.0 to 47.2) | 35.2 (25.8 to 44.7) | 28.6 (20.2 to 38.2) |
An absolute Partial Mayo Score of \<=2 corresponds to remission. However, this endpoint was incorrectly stated in the protocol and instead of "absolute Partial Mayo Score \<=2", it was stated as "change from baseline in Partial Mayo Score \<=2".
No measurements were reported for this outcome.
The Mayo Score is a tool designed to measure disease activity for UC. Scoring ranges from 0 to 12 points and consists of 4 subscores, each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopic readings from the local and the central reader were considered for analysis. The central reading was used as the primary analysis and the local readings were used for the sensitivity analyses.
| units on a scale | Placebo | PF-00547659 7.5 mg | PF-00547659 22.5 mg | PF-00547659 75 mg | PF-00547659 225 mg |
|---|---|---|---|---|---|
| Centrally read baseline (n=73,71,72,71,70) | 8.4 ± 1.71 | 8.7 ± 1.65 | 8.1 ± 1.63 | 8.4 ± 1.94 | 8.7 ± 1.60 |
| Centrally read change (n=67,63,69,67,63) | -1.5 ± 2.42 | -2.4 ± 2.78 | -2.9 ± 2.49 | -2.5 ± 2.74 | -2.9 ± 2.78 |
| Locally read baseline (n=73,70,72,70,70) | 8.4 ± 1.72 | 8.8 ± 1.59 | 8.1 ± 1.72 | 8.3 ± 1.99 | 8.6 ± 1.62 |
| Locally read change (n=67,62,70,66,64) | -1.7 ± 2.55 | -2.7 ± 3.05 | -3.1 ± 2.70 | -2.7 ± 2.92 | -3.1 ± 3.07 |
The Mayo Score is a tool designed to measure disease activity for UC. Scoring ranges from 0 to 12 points and consists of 4 subscores (stool frequency, rectal bleeding, PGA, findings on flexible sigmoidoscopy), each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopic readings from the local and the central reader were considered for analysis. The central reading was used as the primary analysis and the local readings were used for the sensitivity analyses. Changes from baseline in the subscore of less than (\<) 0, 0, and \>0 corresponded to improvement (imp), no change (NC), and worsening (wors) in that specific subscore.
| percentage of participants | Placebo | PF-00547659 7.5 mg | PF-00547659 22.5 mg | PF-00547659 75 mg | PF-00547659 225 mg |
|---|---|---|---|---|---|
| Imp in Stool frequency, W4 (n=67,64,71,69,65) | 26.87 (-2.043 to -1.014) | 46.88 (-2.944 to -1.881) | 36.62 (-3.570 to -2.550) | 30.43 (-3.162 to -2.131) | 43.08 (-3.337 to -2.270) |
| NC in Stool frequency, W4 (n=67,64,71,69,65) | 59.70 (-2.280 to -1.171) | 42.19 (-3.241 to -2.084) | 60.56 (-3.866 to -2.775) | 63.77 (-3.357 to -2.236) | 52.31 (-3.583 to -2.442) |
| Wors in Stool frequency, W4 (n=67,64,71,69,65) | 13.43 | 10.94 | 2.82 | 5.80 | 4.62 |
| Imp in Stool frequency, W8 (n=71,63,71,69,68) | 28.17 | 49.21 | 43.66 | 49.28 | 51.47 |
| NC in Stool frequency, W8 (n=71,63,71,69,68) | 60.56 | 42.86 | 53.52 | 46.38 | 48.53 |
| Wors in Stool frequency, W8 (n=71,63,71,69,68) | 11.27 | 7.94 | 2.82 | 4.35 | 0 |
| Imp in Stool frequency, W12 (n=67,63,71,68,64) | 35.82 | 49.21 | 56.34 | 45.59 | 56.25 |
| NC in Stool frequency, W12 (n=67,63,71,68,64) | 52.24 | 41.27 | 38.03 | 48.53 | 37.50 |
| Wors in Stool frequency, W12 (n=67,63,71,68,64) | 11.94 | 9.52 | 5.63 | 5.88 | 6.25 |
| Imp in Rectal Bleeding, W4 (n=67,64,71,69,65) | 22.39 | 48.44 | 42.25 | 42.03 | 49.23 |
| NC in Rectal Bleeding, W4 (n=67,64,71,69,65) | 62.69 | 42.19 | 57.75 | 53.62 | 44.62 |
| Wors in Rectal Bleeding, W4 (n=67,64,71,69,65) | 14.93 | 9.38 | 0 | 4.35 | 6.15 |
| Imp in Rectal Bleeding, W8 (n=71,63,71,69,68) | 33.80 | 50.79 | 40.85 | 46.38 | 64.71 |
| NC in Rectal Bleeding, W8 (n=71,63,71,69,68) | 54.93 | 36.51 | 50.70 | 44.93 | 33.82 |
| Wors in Rectal Bleeding, W8 (n=71,63,71,69,68) | 11.27 | 12.70 | 8.45 | 8.70 | 1.47 |
| Imp in Rectal Bleeding, W12 (n=67,63,71,68,64) | 37.31 | 53.97 | 50.70 | 47.06 | 60.94 |
| NC in Rectal Bleeding, W12 (n=67,63,71,68,64) | 50.75 | 34.92 | 42.25 | 45.59 | 35.94 |
| Wors in Rectal Bleeding, W12 (n=67,63,71,68,64) | 11.94 | 11.11 | 7.04 | 7.35 | 3.13 |
| Imp in PGA, W4 (n=67,64,71,69,65) | 47.76 | 57.81 | 56.34 | 56.52 | 60.00 |
| NC in PGA, W4 (n=67,64,71,69,65) | 49.25 | 34.38 | 39.44 | 42.03 | 35.38 |
| Wors in PGA, W4 (n=67,64,71,69,65) | 2.99 | 7.81 | 4.23 | 1.45 | 4.62 |
| Imp in PGA, W8 (n=71,63,71,69,68) | 59.15 | 61.90 | 66.20 | 62.32 | 67.65 |
| NC in PGA, W8 (n=71,63,71,69,68) | 33.80 | 30.16 | 30.99 | 37.68 | 30.88 |
| Wors in PGA, W8 (n=71,63,71,69,68) | 7.04 | 7.94 | 2.82 | 0 | 1.47 |
| Imp in PGA, W12 (n=67,63,71,68,64) | 50.75 | 61.90 | 64.79 | 55.88 | 57.81 |
| NC in PGA, W12 (n=67,63,71,68,64) | 43.28 | 31.75 | 32.39 | 39.71 | 32.81 |
| Wors in PGA, W12 (n=67,63,71,68,64) | 5.97 | 6.35 | 2.82 | 4.41 | 9.38 |
The Mayo Score is a tool designed to measure disease activity for UC. Scoring ranges from 0 to 12 points and consists of 4 subscores (stool frequency, rectal bleeding, PGA, findings on flexible sigmoidoscopy), each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopic readings from the local and the central reader were considered for analysis. The central reading was used as the primary analysis and the local readings were used for the sensitivity analyses. Changes from baseline in the subscore of \<0, 0, and \>0 corresponded to improvement (imp), no change (NC), and worsening (wors) in that specific subscore.
| percentage of participants | Placebo | PF-00547659 7.5 mg | PF-00547659 22.5 mg | PF-00547659 75 mg | PF-00547659 225 mg |
|---|---|---|---|---|---|
| Imp (n=67,63,69,67,63) | 25.37 (-2.043 to -1.014) | 28.57 (-2.944 to -1.881) | 47.83 (-3.570 to -2.550) | 47.76 (-3.162 to -2.131) | 39.68 (-3.337 to -2.270) |
| NC (n=67,63,69,67,63) | 61.19 (-2.280 to -1.171) | 60.32 (-3.241 to -2.084) | 49.28 (-3.866 to -2.775) | 46.27 (-3.357 to -2.236) | 57.14 (-3.583 to -2.442) |
| Wors (n=67,63,69,67,63) | 13.43 | 11.11 | 2.90 | 5.97 | 3.17 |
Fecal calprotectin was one of the pharmacodynamic (PD) biomarkers of the study.
| percent change | Placebo | PF-00547659 7.5 mg | PF-00547659 22.5 mg | PF-00547659 75 mg | PF-00547659 225 mg |
|---|---|---|---|---|---|
| Week 4 (n=62,57,68,67,60) | -25.62 (-43.49 to -2.09) | -40.21 (-55.56 to -19.54) | -23.50 (-44.27 to 5.00) | -46.22 (-61.46 to -24.95) | -39.27 (-56.74 to -14.75) |
| Week 8 (n=67,57,67,63,65) | -21.68 (-39.62 to 1.60) | -44.49 (-60.05 to -22.88) | -44.77 (-60.49 to -22.80) | -57.20 (-69.74 to -39.45) | -49.54 (-65.08 to -27.07) |
| Week 12 (n=61,55,64,64,59) | -22.59 (-42.68 to 4.54) | -56.34 (-69.39 to -37.72) | -58.41 (-72.26 to -37.65) | -56.72 (-71.67 to -33.88) | -64.52 (-76.92 to -45.43) |
hsCRP was one of the PD biomarkers of the study.
| percent change | Placebo | PF-00547659 7.5 mg | PF-00547659 22.5 mg | PF-00547659 75 mg | PF-00547659 225 mg |
|---|---|---|---|---|---|
| Week 4 (n=67,64,69,71,65) | -11.60 (-25.69 to 5.17) | -19.17 (-34.22 to -0.67) | -26.90 (-39.41 to -11.82) | -35.21 (-49.10 to -17.55) | -17.70 (-30.08 to -3.13) |
| Week 8 (n=71,63,69,71,68) | -2.42 (-22.75 to 23.25) | -6.00 (-23.09 to 14.89) | -31.43 (-44.11 to -15.88) | -43.15 (-54.57 to -28.86) | -22.70 (-36.72 to -5.59) |
| Week 12 (n=67,62,68,71,64) | 14.85 (-11.16 to 48.48) | 4.51 (-18.02 to 33.25) | -20.40 (-38.61 to 3.22) | -15.96 (-33.12 to 5.60) | 2.31 (-18.48 to 28.42) |
IBDQ: Psychometrically validated patient reported outcome (PRO) instrument for measuring disease-specific quality of life (QOL) in participants with inflammatory bowel disease. IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). Total score is the sum of each item score, ranged from 32 to 224 with higher score indicating better QOL. Positive change in total score indicated improvement in QOL.
| units on a scale | Placebo | PF-00547659 7.5 mg | PF-00547659 22.5 mg | PF-00547659 75 mg | PF-00547659 225 mg |
|---|---|---|---|---|---|
| Baseline (BL)(n=69,68,65,71,66) | 128.0 ± 30.69 | 122.1 ± 38.82 | 133.4 ± 34.79 | 128.0 ± 32.42 | 132.3 ± 36.84 |
| Change at W12 (n=62,55,61,64,54) | 19.8 ± 34.08 | 20.1 ± 35.24 | 32.7 ± 34.10 | 32.1 ± 31.70 | 36.2 ± 29.45 |
IBDQ: Psychometrically validated PRO instrument for measuring disease-specific QOL in participants with inflammatory bowel disease. IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). Total score is the sum of each item score, ranged from 32 to 224 with higher score indicating better QOL. Positive change in total score indicated improvement in QOL. There are 4 individual domains under the IBDQ: bowel function (fx)/symptoms (score range of 10-70), systemic symptoms (score range of 5-35), emotional status/fx (score range of 12-84), and social fx (score range of 5-35). As with total score, higher scores indicate better QOL in that domain.
| units on a scale | Placebo | PF-00547659 7.5 mg | PF-00547659 22.5 mg | PF-00547659 75 mg | PF-00547659 225 mg |
|---|---|---|---|---|---|
| BL, bowel fx (n=69,68,65,71,66) | 38.9 ± 9.96 | 37.0 ± 12.23 | 41.7 ± 10.60 | 38.5 ± 9.95 | 41.0 ± 11.37 |
| Change at W12, bowel fx (n=62,55,61,64,54) | 7.4 ± 11.93 | 6.9 ± 12.51 | 11.3 ± 11.05 | 11.8 ± 12.07 | 12.8 ± 11.45 |
| BL, emotional fx (n=69,68,65,71,66) | 50.4 ± 12.60 | 48.4 ± 15.39 | 51.2 ± 14.70 | 50.4 ± 13.73 | 51.3 ± 15.92 |
| Change at W12, emotional fx (n=62,55,61,64,54) | 5.9 ± 11.91 | 6.6 ± 12.22 | 10.8 ± 13.85 | 10.0 ± 12.04 | 12.0 ± 11.40 |
| BL, systemic symptoms (SS)(n=69,68,65,71,66) | 18.1 ± 5.62 | 18.2 ± 6.81 | 19.6 ± 5.98 | 18.4 ± 6.42 | 19.0 ± 5.97 |
| Change at W12, SS (n=62,55,61,64,54) | 3.3 ± 6.67 | 3.1 ± 5.95 | 4.7 ± 5.91 | 4.9 ± 5.49 | 4.8 ± 5.05 |
| BL, social fx (n=69,68,65,71,66) | 20.6 ± 7.87 | 18.5 ± 8.07 | 20.9 ± 7.37 | 20.7 ± 6.99 | 20.9 ± 7.73 |
| Change at W12, social fx (n=62,55,61,64,54) | 3.3 ± 6.27 | 3.6 ± 7.33 | 5.9 ± 6.51 | 5.4 ± 6.90 | 6.6 ± 6.58 |
IBDQ: Psychometrically validated PRO instrument for measuring disease-specific QOL in participants with inflammatory bowel disease. IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). Total score is sum of each item score, ranged from 32 to 224 with higher score indicating better QOL. Positive change in total score indicated improvement in QOL. A score of \>=170 corresponds to clinical remission.
| percentage of participants | Placebo | PF-00547659 7.5 mg | PF-00547659 22.5 mg | PF-00547659 75 mg | PF-00547659 225 mg |
|---|---|---|---|---|---|
| Percentage of Participants With an Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score of More Than or Equal to (>=) 170 at Week 12 | 36.9 (27.4 to 47.5) | 36.8 (26.9 to 47.9) | 55.6 (45.0 to 66.3) | 46.9 (36.1 to 57.5) | 48.1 (36.3 to 59.4) |
An adverse event (AE) was any untoward medical occurrence attributed to study drug in a participant who received study drug. TEAEs are defined as newly occurring AEs or those worsening after first dose. AEs comprised both SAEs and non-SAEs. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
| participants | Placebo | PF-00547659 7.5 mg | PF-00547659 22.5 mg | PF-00547659 75 mg | PF-00547659 225 mg |
|---|---|---|---|---|---|
| With TEAEs | 39 | 41 | 36 | 43 | 43 |
| With SAEs | 4 | 11 | 1 | 3 | 3 |
| Withdrawals due to TEAEs | 2 | 5 | 0 | 3 | 1 |
| nanograms (ng)/milliliter (mL) | Placebo | PF-00547659 7.5 mg | PF-00547659 22.5 mg | PF-00547659 75 mg | PF-00547659 225 mg |
|---|---|---|---|---|---|
| Maximum Serum PF-00547659 Concentration Achieved | — | 929.4 ± 1977.8 | 2062 ± 1395.5 | 6576 ± 2146.0 | 21470 ± 4788.4 |
Collected over Screening till Week 36 or Early Withdrawal, whichever was later.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 4/73 (5.5%) | 17/73 (23.3%) |
| PF-00547659 7.5 mg | — | 11/71 (15.5%) | 16/71 (22.5%) |
| PF-00547659 22.5 mg | — | 2/70 (2.9%) | 15/70 (21.4%) |
| PF-00547659 75 mg | — | 4/73 (5.5%) | 14/73 (19.2%) |
| PF-00547659 225 mg | — | 3/70 (4.3%) | 18/70 (25.7%) |
| Event | Placebo | PF-00547659 7.5 mg | PF-00547659 22.5 mg | PF-00547659 75 mg | PF-00547659 225 mg |
|---|---|---|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 1/73 | 6/71 | 0/70 | 2/73 | 0/70 |
| DiarrhoeaGastrointestinal disorders | 2/73 | 0/71 | 0/70 | 0/73 | 0/70 |
| Retinal artery embolismEye disorders | 0/73 | 0/71 | 1/70 | 0/73 | 0/70 |
| Abdominal painGastrointestinal disorders | 0/73 | 0/71 | 0/70 | 0/73 | 1/70 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/73 | 0/71 | 0/70 | 0/73 | 1/70 |
| MigraineNervous system disorders | 0/73 | 0/71 | 0/70 | 1/73 | 1/70 |
| Tension headacheNervous system disorders | 0/73 | 0/71 | 0/70 | 0/73 | 1/70 |
| Colectomy totalSurgical and medical procedures | 0/73 | 0/71 | 1/70 | 0/73 | 0/70 |
| Anal fistulaGastrointestinal disorders | 0/73 | 1/71 | 0/70 | 0/73 | 0/70 |
| ConstipationGastrointestinal disorders | 0/73 | 1/71 | 0/70 | 0/73 | 0/70 |
| Event | Placebo | PF-00547659 7.5 mg | PF-00547659 22.5 mg | PF-00547659 75 mg | PF-00547659 225 mg |
|---|---|---|---|---|---|
| HeadacheNervous system disorders | 6/73 | 5/71 | 7/70 | 4/73 | 8/70 |
| Abdominal painGastrointestinal disorders | 2/73 | 6/71 | 3/70 | 2/73 | 1/70 |
| NauseaGastrointestinal disorders | 3/73 | 6/71 | 1/70 | 1/73 | 4/70 |
| NasopharyngitisInfections and infestations | 3/73 | 0/71 | 3/70 | 5/73 | 4/70 |
| VomitingGastrointestinal disorders | 3/73 | 1/71 | 4/70 | 0/73 | 2/70 |
| AnaemiaBlood and lymphatic system disorders | 0/73 | 0/71 | 2/70 | 4/73 | 2/70 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/73 | 1/71 | 0/70 | 1/73 | 0/70 |
| Age, Continuous(years) | Placebo | PF-00547659 7.5 mg | PF-00547659 22.5 mg | PF-00547659 75 mg | PF-00547659 225 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 38.6 ± 12.7 | 41.3 ± 12.5 | 42.1 ± 14.7 | 37.7 ± 12.4 | 41.3 ± 13.2 | 40.2 ± 13.2 |
| Sex: Female, Male(Participants) | Placebo | PF-00547659 7.5 mg | PF-00547659 22.5 mg | PF-00547659 75 mg | PF-00547659 225 mg | Total |
|---|---|---|---|---|---|---|
| Female | 29 | 32 | 25 | 35 | 28 | 149 |
| Male | 44 | 39 | 45 | 38 | 42 | 208 |
Showing the first 100 of 190 sites across 21 countries. Choose a country and city above to see the rest.
Ran from Nov 2012 to primary completion in Sep 2014, 22 months.
Results were first posted in Mar 2017, 2 years 6 months after primary completion. A results delay was requested in Nov 2015.
Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 22 months is below that.
Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ontamalimab